Medicare delayed a plan to make insurance companies cover GLP-1 drugs Wegovy and Zepbound. Instead, Medicare will cover the ...

Medicare's GLP-1 bridge program launches July 1 with a $50 monthly copay after major insurers rejected the original BALANCE ...

Eli Lilly (LLY) stock and Novo Nordisk (NONOF) stock are in focus as Medicare extends interim coverage for GLP-1 weight loss ...

Meanwhile — in a late-breaking moment — federal officials are having to pivot on the fly after insurers panned the effort to ...

The Trump administration is delaying a voluntary model that aimed to expand access to GLP-1s in Part D after pushback from ...

UnitedHealth Group Inc. sees difficulties with the Trump administration’s plan to cover obesity drugs in Medicare next year, ...

Two of the biggest insurance providers have expressed reluctance to participate in the government’s BALANCE program that ...

Eli Lilly (LLY) stock and Novo Nordisk (NVO) stock slip as health insurers remain undecided on a U.S. program to expand ...

Some health insurers are pushing back against a new program that will allow Medicare beneficiaries to pay $50 per month for ...

Not a subscriber? Sign up here to get this newsletter in your inbox. The Trump administration wants to test a program ...

By adding digital health and nutrition support to Rx access, the retailer hopes to win share with the weight-loss army.